Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 3:39 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 17,120 matching trials from the live ClinicalTrials.gov search.

Filters: Philadelphia, Pennsylvania Clear all

Conditions: Severe Hypertriglyceridemia
Interventions: Plozasiran Injection, Placebo; Drug
Lead sponsor: Arrowhead Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 311 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 50
States / cities: Birmingham, Alabama • Mobile, Alabama • Beverly Hills, California + 44 more

Conditions: Onychomycosis
Interventions: IDP-108, Vehicle; Drug
Lead sponsor: Dow Pharmaceutical Sciences; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 870 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 33
States / cities: Birmingham, Alabama • Phoenix, Arizona • San Diego, California + 29 more

Conditions: Preterm Birth, Health Care Utilization, Tobacco Use, Contraceptive Usage, Depression, Weight, Birth
Interventions: Care Coordination after Preterm Birth (CCAPB); Behavioral
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 14 Years to 45 Years · Female only
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Epilepsy
Interventions: Levetiracetam; Drug
Lead sponsor: UCB Pharma SA; Industry
Eligibility: 1 Month to 4 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 6
States / cities: San Diego, California • Buffalo, New York • Philadelphia, Pennsylvania + 3 more

Conditions: Treatment-resistant Depression
Interventions: Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 346 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 37
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Garden Grove, California + 34 more

Conditions: Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: ECTEINASCIDIN 743; Drug
Lead sponsor: Children's Oncology Group; Network
Eligibility: 1 Year to 17 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2005
U.S. locations: 42
States / cities: Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 34 more

Conditions: Breast Cancer, Lymphoma
Interventions: Atorvastatin, Placebo; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 21 Years to 100 Years
Enrollment: 279 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 51
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Chicago, Illinois + 35 more

Conditions: Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular
Interventions: Not listed
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 53
States / cities: Hot Springs, Arkansas • Boulder, Colorado • Pensacola, Florida + 35 more

Conditions: Atopic Dermatitis
Interventions: Pimecrolimus Cream, 1%, Placebo Cream; Drug
Lead sponsor: Mylan Inc.; Industry
Eligibility: 8 Years and older
Enrollment: 654 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 25
States / cities: Boynton Beach, Florida • Coral Gables, Florida • Miami, Florida + 21 more

Conditions: Obesity
Interventions: Semaglutide, Placebo (semaglutide); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 529 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 50
States / cities: Fairhope, Alabama • Beverly Hills, California • Los Angeles, California + 41 more

Conditions: Syncope
Interventions: Not listed
Lead sponsor: University of Pennsylvania; Other
Eligibility: 60 Years and older
Enrollment: 3,707 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 10
States / cities: Sacramento, California • Boston, Massachusetts • Royal Oak, Michigan + 7 more

Conditions: Cardiac Arrhythmia
Interventions: Dataq Instruments DI-158; Device
Lead sponsor: Drexel University College of Medicine; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Urinary Retention, Prostatic Hyperplasia, Benign Prostatic Hypertrophy
Interventions: Alfuzosin (SL770499); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 55 Years and older · Male only
Enrollment: 1,522 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 35
States / cities: Huntsville, Alabama • La Mesa, California • San Bernardino, California + 32 more

Conditions: Heart Failure
Interventions: vicadrostat, empagliflozin, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 4,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 89
States / cities: Beverly Hills, California • Covina, California • Encinitas, California + 75 more

Conditions: Atopic Dermatitis
Interventions: Lebrikizumab; Biological
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 12 Years and older
Enrollment: 1,153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 160
States / cities: Anniston, Alabama • Birmingham, Alabama • Scottsdale, Arizona + 124 more

Conditions: Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy
Interventions: Aficamten, Placebo; Drug
Lead sponsor: Cytokinetics; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 60
States / cities: Birmingham, Alabama • La Jolla, California • Los Angeles, California + 46 more

Conditions: Prostate Cancer
Interventions: Tinengotinib, abiraterone acetate with prednisone, Enzalutamide; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 12
States / cities: New Haven, Connecticut • Basking Ridge, New Jersey • Middletown, New Jersey + 8 more

Conditions: HER2-positive Breast Cancer
Interventions: Atezolizumab, Paclitaxel, Trastuzumab, Pertuzumab; Drug
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Overweight and Obesity
Interventions: Behavioral weight loss intervention; Behavioral
Lead sponsor: Drexel University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 128 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Intracerebral Hemorrhage
Interventions: Intravenous nicardipine hydrochloride; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 116
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 87 more

Conditions: Brain Tumor, Central Nervous System Tumor
Interventions: carboplatin, temozolomide, vincristine sulfate; Drug
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 10 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2013
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Non-muscle Invasive Bladder Cancer (NMIBC)
Interventions: inodiftagene vixteplasmid; Drug
Lead sponsor: Anchiano Therapeutics Israel Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 48
States / cities: Anchorage, Alaska • Gilbert, Arizona • Phoenix, Arizona + 40 more

Conditions: Rheumatoid Arthritis
Interventions: Certolizumab pegol (CZP), Placebo; Drug · Other
Lead sponsor: UCB Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 1,648 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 101
States / cities: Birmingham, Alabama • Montgomery, Alabama • Phoenix, Arizona + 98 more

Conditions: Cardiovascular Disease
Interventions: Education; Behavioral
Lead sponsor: Yale University; Other
Eligibility: Not listed
Enrollment: 92,057 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2014
U.S. locations: 14
States / cities: Long Beach, California • San Francisco, California • New Haven, Connecticut + 10 more

Search by objective public record fields.

Study of Plozasiran in Adults With Severe Hypertriglyceridemia

Safety and Efficacy of Topical IDP-108 Versus Vehicle in Patients With Onychomycosis

Health and Wellness After Preterm Birth

Open-label Study of Levetiracetam Intravenous Infusion in Children (1 Month-4 Years Old) With Epilepsy

A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

Ecteinascidin 743 in Treating Children With Refractory Solid Tumors

Preventing Anthracycline Cardiovascular Toxicity With Statins (PREVENT)

Connect® Lymphoma Disease Registry: A US-Based Prospective Observational Cohort Study

Bioequivalence Study of Pimecrolimus Cream, 1% and Elidel® Cream, 1% in Mild to Moderate Atopic Dermatitis

Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity

Improving Syncope Risk Stratification in Older Adults

Heart Rate Variability Changes During Cardiac Surgery And The Incidence Of Post-Operative Cardiac Arrhythmias

Clinical Trial in Males With BPH (Enlarged Prostate)

A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart

Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)

A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)

A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer

Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer

Behavioral Treatment for Weight Loss

Antihypertensive Treatment of Acute Cerebral Hemorrhage-II

Carboplatin, Vincristine, and Temozolomide in Treating Children With Progressive and/or Symptomatic Low-Grade Glioma

Codex: Study of Inodiftagene Vixteplasmid (BC-819) in Unresponsive NMIBC

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis

Implementation of Practice Standards for ECG Monitoring